Cerliponase alfa (trade name Brineura) is a recombinant form of a human enzyme called tripeptidyl peptidase 1 (TPP1). It is a prescription medicine used to treat a rare, progressive neurodegenerative disorder called CLN2 disease, also known as late infantile neuronal ceroid lipofuscinosis type 2 (LINCL). It is used to slow the loss of abilities in children between 3 and 8 years of age. It is administered as an infusion into the cerebrospinal fluid every other week. Common side effects may include fever, headache, nausea, vomiting, and injection site reactions.
Cerliponase alfa: Enzyme Replacement Therapy for a Rare Disease
Cerliponase alfa, sold under the brand name Zorbive, is a prescription medication classified as enzyme replacement therapy. It is specifically used to treat a rare and progressive neurodegenerative lysosomal storage disorder called Late Infantile Batten Disease (CLN2).
Function:
- Enzyme replacement: CLN2 is caused by a deficiency in the enzyme tripeptidyl peptidase 1 (TPP-1). This enzyme plays a crucial role in breaking down certain cellular waste products within lysosomes, which are compartments within cells responsible for waste disposal.
- Cerliponase alfa replaces the missing TPP-1 enzyme, allowing the body to break down the accumulated waste products in the brain and nervous system. This helps to slow down the progression of the disease and potentially improve some symptoms.
Important Points:
- Rare disease: CLN2 is a very rare autosomal recessive genetic disorder, affecting approximately 1 in 100,000 births.
- Early diagnosis crucial: Early diagnosis and initiation of treatment with cerliponase alfa are critical for maximizing potential benefits.
- Route of administration: Cerliponase alfa is administered by intrathecal infusion (injection into the cerebrospinal fluid surrounding the brain and spinal cord) every two weeks.
- Potential side effects: Common side effects can include:
- Headache
- Fever
- Nausea and vomiting
- Fatigue
- Back pain
- Infusion site reactions
- Not a cure: Cerliponase alfa is not a cure for CLN2, but it can help to slow down the disease progression and improve some symptoms, potentially leading to a better quality of life for patients.
Remember:
- This information is for general knowledge only and should not be a substitute for professional medical advice.
- If you have concerns about CLN2 or any other medical condition, always consult with a qualified healthcare professional for diagnosis, treatment options, and personalized guidance.